All In Biotech

Free tool

FAERS Monitor: Safyral

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming NDA 022574 or its brand name (Safyral, Drospirenone, Ethinyl Estradiol, Levomefolate Calcium). Reports on generic versions are filed under their own applications.

Reports

246

Serious

145

59% of reports

Hospitalization

78

Death reported

5

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • injury67
  • pulmonary embolism65
  • deep vein thrombosis64
  • pain45
  • emotional distress41
  • anxiety33
  • general physical health deterioration28
  • anhedonia27
  • off label use18
  • drug dose omission14
  • thrombosis13
  • metrorrhagia10
  • nausea10
  • pain in extremity9
  • dyspnoea7

Reports by year received

View as table
YearReports
20101
201124
201251
201361
201456
201527
201612
20176
20182
20191
20202
20212
20231

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,053,913 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
anhedoniaSignal2787.961.62,235
deep vein thrombosisSignal6484.368.35,195
injurySignal6781.666.55,264
pulmonary embolismSignal6558.547.53,631
metrorrhagiaSignal1050.227.3434
emotional distressSignal4129.021.91,085
general physical health deteriorationSignal2820.714.6508
thrombosisSignal1313.88.1143
anxietySignal339.97.2259
drug dose omissionSignal147.24.470
painSignal456.34.8200
pain in extremitySignal92.61.48
off label use181.81.15
nausea101.10.60
dyspnoea71.10.50

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.